Investor Presentation

78 Investor presentation First six months of 2022 Haemophilia is a rare disease with severe unmet medical needs and the market is highly competitive Recombinant haemophilia product sales DKK billion 50 40 30 20 10 0 -2% +7% +9% Novo NordiskⓇ 2017 2021 2017 Haemophilia with inhibitors Haemophilia A Patients1 ~ 6,000 ~ 165,000 2021 2017 2021 Haemophilia B ~ 35,000 NovoSevenⓇ susoctocog alfa² Coagil³ Feiba4 Hemlibra NovoEight® EsperoctⓇ Eloctate Xyntha/Refacto Helixate/Afstyla RefixiaⓇ/RebinynⓇ Kogenate/Kovaltry/Jivi Advate/Adynovate Hemlibra Benefix Rixubis Idelvion Alprolix 1 Total diagnosed patients in segment, WFH annual survey 2020 (numbers may be understated as 120 out of 147 countries responded); 2 Obizur only indicated for acquired haemophilia; 3 Plasma-derived; 4 Part of the Hemlibra sales is used for treatment of haemophilia A patients in 2021 Source: Company reported sales and Evaluate

View entire presentation